Company intelligence / Profile preview

Orbus Therapeutics

Palo Alto, California, United Statesorbustherapeutics.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The STELLAR study in patients with grade 3 astrocytoma completed in 2024. The primary efficacy endpoint of overall survival was not statistically significant, however, a clinically meaningful improvement in OS and PFS was seen in a defined subgroup of patients with grade 3 astrocytoma. The combination of eflornithine and lomustine demonstrated clinically meaningful improvements in overall survival and progression-free survival in patients with recurrent astrocytoma, IDH mutant grade 3.[6][7]

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecules (eflornithine)
Industry: Biotech

Drug pipeline

1 asset

eflornithine

Phase 3

Indications: Recurrent anaplastic astrocytoma

Beyond the preview

Go deeper on Orbus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orbus Therapeutics.

Explore the full profile